SIGN UP
LOG IN
N
NAUT
Nautilus Biotechnology Inc
0.69
-0.02-3.45%After Hours: 0.6888 +0.0004 +0.06%19:48 04/25 EDT
OPEN/PREV CLOSE0.7044/0.7130
TODAY RANGE0.6650-0.7119
VOL276.30K
MARKET CAP86.84M
52 WEEK RANGE0.6600-3.090
AVG VOL (3M)140.75K
% TURNOVER0.22%
TURNOVER--
P/E (TTM)-1.2199
% RANGE6.58%
EPS(TTM)-0.5643
P/E(FORWARD)-1.1869
P/B0.4159
BVPS1.655
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP49.05M
SHARES OUTSTANDING126.15M
NEXT EARNINGS--
FREE FLOAT71.26M
LOT SIZE1
EX-DIV DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·03/22 02:01
Nautilus Biotechnology’s CEO Makes a Bold Stock Move!
TipRanks·03/04 00:13
Nautilus Biotechnology’s Earnings Call: Progress Amid Challenges
Seeking Alpha·02/28 23:59
Nautilus: Trading Below An Albeit Lower Net Cash Figure
TipRanks·02/28 13:17
Nautilus Biotechnology price target lowered to $2.50 from $4 at Guggenheim
TipRanks·02/28 04:38
TD Cowen Reaffirms Their Buy Rating on Nautilus Biotechnolgy (NAUT)
TipRanks·02/28 04:16
Nautilus Biotechnology Reports 2024 Financial Results
TipRanks·02/27 13:18
Nautilus Biotechnology reports Q4 EPS (14c), consensus (18c)
Seeking Alpha·02/27 13:15
Nautilus Biotechnology beats Q4 profit estimates, issues outlook
Dow Jones·02/27 13:02
*Nautilus Biotechnology 4Q Loss $17.6M >NAUT
Reuters·02/27 13:00
BRIEF-Nautilus Biotechnology Q4 EPS USD -0.14
Dow Jones·02/27 13:00
Press Release: Nautilus Biotechnology Reports -2-
Benzinga·02/27 12:37
Nautilus Biotechnology Q4 GAAP EPS $(0.14) Beats $(0.16) Estimate
Same Industry
Name/Symbol
Change%
Price
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
② More than 40M Downloads Globally : data based on Webull Technologies Limited's internal statistics as of July 14, 2023.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
② More than 40M Downloads Globally : data based on Webull Technologies Limited's internal statistics as of July 14, 2023.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.